IL-1: discoveries, controversies and future directions (Q37702138)

22 August 2017

1 reference

title

IL-1: discoveries, controversies and future directions (English)

1 reference

22 August 2017

1

Charles A Dinarello

1 reference

PubMed ID

20201008

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

European Journal of Immunology

22 August 2017

1 reference

22 August 2017

40

1 reference

22 August 2017

3

1 reference

22 August 2017

599-606

1 reference

Fever: The Old and the New

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

Human leukocytic pyrogen: purification and development of a radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Nucleotide sequence of human monocyte interleukin 1 precursor cDNA

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Preliminary report: effects of interleukin-1 on platelet counts

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Studies on the pathogenesis of fever. I. The presence of transferable pyrogen in the blood stream following the injection of typhoid vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Release of Endogenous Pyrogen by Human Monocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Endogenous pyrogen production by Hodgkin's disease and human histiocytic lymphoma cell lines in vitro

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin-1 and the Pathogenesis of the Acute-Phase Response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Demonstration and characterization of two distinct human leukocytic pyrogens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Cloning and expression of murine interleukin-1 cDNA in Escherichia coli

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Drosophila Toll and IL-1 receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Recognition of endotoxin by cells leading to transmembrane signaling

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Regulation of adaptive immunity by the innate immune system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Identification of a key pathway required for the sterile inflammatory response triggered by dying cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Isolation and characterization of a primitive interleukin-1-like protein from an invertebrate, Asterias forbesi

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Inflammatory caspases and inflammasomes: master switches of inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Immunological and inflammatory functions of the interleukin-1 family

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Signaling by ROS drives inflammasome activation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Superoxide dismutase 1 regulates caspase-1 and endotoxic shock

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Pathogen-induced interleukin-1beta processing and secretion is regulated by a biphasic redox response.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Cancer prevention. Beta-carotene: helpful or harmful?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Antioxidants and CVD.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The NLRP3 inflammasome, a target for therapy in diverse disease states

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Increased secretion and expression of myostatin in skeletal muscle from extremely obese women.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin-1β–Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen–Induced Tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Fever and antipyresis in the lizard Dipsosaurus dorsalis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Multiple biological activities of a partially purified leukocytic endogenous mediator

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Collagenase Production by Rheumatoid Synovial Cells: Stimulation by a Human Lymphocyte Factor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Identification of catabolin, a protein fro synovium which induces degradation of cartilage in organ culture

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Chromosomal localization of TIL, a gene encoding a protein related to the Drosophila transmembrane receptor Toll, to human chromosome 4p14.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040319

7 January 2021

Identifiers

DOI

10.1002/EJI.201040319

1 reference

22 August 2017

1 reference

PubMed ID

20201008